<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, diagnosis, and staging of esophageal cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, diagnosis, and staging of esophageal cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, diagnosis, and staging of esophageal cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John R Saltzman, MD, FACP, FACG, FASGE, AGAF
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael K Gibson, MD, PhD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas A Howell, MD, FASGE, FACG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Squamous cell carcinoma (SCC) and adenocarcinoma account for over 95 percent of esophageal malignant tumors. For most of the 20
         <sup>
          th
         </sup>
         century, SCC predominated. In the 1960s, SCC accounted for more than 90 percent of esophageal tumors in the United States, and adenocarcinomas were considered so uncommon that some authorities questioned their existence. However, over time, the incidence of esophageal adenocarcinoma (predominantly arising in the distal esophagus and esophagogastric junction [EGJ]) has increased dramatically in Western countries such that adenocarcinoma now accounts for &gt;60 percent of all esophageal cancers in the United States [
         <a href="#rid1">
          1
         </a>
         ]. In contrast, worldwide, SCC still predominates [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">
          "Epidemiology and pathobiology of esophageal cancer"
         </a>
         .)
        </p>
        <p>
         Esophageal SCCs and adenocarcinomas differ in a number of features, including tumor location and predisposing factors  (
         <a class="graphic graphic_table graphicRef78167" href="/z/d/graphic/78167.html" rel="external">
          table 1
         </a>
         ). Smoking and alcohol are major risk factors for SCC, while Barrett's esophagus (BE) with intestinal metaplasia (a complication of gastroesophageal reflux disease [GERD]), obesity, and smoking are the risk factors for adenocarcinoma [
         <a href="#rid3">
          3
         </a>
         ]. Although there is little doubt that esophageal SCCs and adenocarcinomas represent two different diseases with characteristic pathogenesis, epidemiology, tumor biology, treatment, and outcomes, whether and how histology influence the therapeutic approach remains controversial. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus", section on 'Squamous cell versus adenocarcinoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">
          "Epidemiology and pathobiology of esophageal cancer"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations, diagnosis, and staging of esophageal cancer are reviewed here. The epidemiology, risk factors, and pathobiology of SCC and adenocarcinoma are covered elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">
          "Epidemiology and pathobiology of esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3975848916">
         <span class="h1">
          IMPORTANCE OF PRETREATMENT STAGING ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is vitally important that newly diagnosed esophageal cancer is accurately staged in order to select appropriate treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with potentially resectable tumors, the choice of initial treatment is highly dependent on clinical stage at diagnosis  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A minority of patients have disease that is limited to the mucosa or submucosa (ie, T1a/bN0), which has a high cure rate from surgical or endoscopic therapy alone. (See
         <a class="medical medical_review" href="/z/d/html/2494.html" rel="external">
          "Management of superficial esophageal cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgery is the primary curative modality for both esophageal and esophagogastric junction (EGJ) cancers that invade through the esophageal wall or are node positive. Long-term outcomes are not satisfactory with resection alone, even if microscopically complete (R0). This poor long-term outcome prompted evaluation of multimodality approaches, which have evolved in parallel for thoracic esophagus and EGJ tumors, respectively. For most patients with T3 or node-positive tumors, combined modality therapy is preferred over surgery alone. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The optimal approach to clinical T2N0 disease is debated, and guidelines from expert groups differ. Some suggest initial chemoradiotherapy for SCC, and either neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinomas of the distal esophagus or EGJ [
         <a href="#rid4">
          4
         </a>
         ]. Others, including the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid5">
          5
         </a>
         ], suggest initial resection for clinical T2N0 adenocarcinomas or SCCs as long as they are &lt;3 cm and well differentiated, but initial chemoradiotherapy for others with either histology who have high-risk disease. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus", section on 'Clinical T2N0 disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Patients with clinical T1/2, node-negative disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regardless of histology, between 50 and 80 percent of patients with esophageal and EGJ cancers present with incurable, locally advanced unresectable or metastatic disease [
         <a href="#rid6">
          6
         </a>
         ]. Survival is often extended by anticancer therapy, but concurrent supportive care is essential. (See
         <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">
          "Management of locally advanced, unresectable and inoperable esophageal cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">
          "Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Selection of patients for any of these therapies is first of all dependent upon accurate staging.
        </p>
        <p class="headingAnchor" id="H369508343">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with advanced thoracic or cervical esophageal carcinoma present with progressive dysphagia and weight loss. Chronic gastrointestinal blood loss from esophageal and esophagogastric junction (EGJ) cancer is common and may result in iron deficiency anemia. Early intramucosal adenocarcinomas of the distal esophagus that are recognized at endoscopy in an area associated with Barrett's esophagus (BE) is usually not symptomatic.
        </p>
        <p class="headingAnchor" id="H1065232198">
         <span class="h2">
          Thoracic esophageal tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite differing histologies, both adenocarcinoma and squamous cell carcinoma (SCC) arising in the thoracic esophagus have similar clinical presentations.
        </p>
        <p>
         In contemporary series, approximately 6 to 10 percent are asymptomatic at the time of diagnosis [
         <a href="#rid7">
          7
         </a>
         ]. Most early (superficial) esophageal cancers in the United States are detected serendipitously or during screening for or surveillance of BE. Early intramucosal cancers are not symptomatic. (See
         <a class="medical medical_review" href="/z/d/html/2494.html" rel="external">
          "Management of superficial esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3458742637">
         <span class="h3">
          Dysphagia and weight loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with locally advanced esophageal cancer, obstruction of the esophagus by the tumor causes progressive dysphagia, often accompanied by weight loss. Dysphagia usually occurs once the esophageal lumen diameter is less than 13 mm (reduction by approximately 70 percent of luminal diameter), which indicates at minimum locally advanced disease. Weight loss is due to changes in diet to accommodate the dysphagia, and tumor-related anorexia may contribute. Approximately 20 percent of patients experience odynophagia (painful swallowing).
        </p>
        <p>
         Early symptoms of esophageal cancer may be subtle and nonspecific. Transient "sticking" of solid food, which may easily be overcome by careful chewing and slower eating, may precede frank dysphagia. The dysphagia gradually progresses from solids to liquids. Patients may also notice retrosternal discomfort or a burning sensation.
        </p>
        <p class="headingAnchor" id="H1254708276">
         <span class="h4">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of dysphagia is broad and includes nonmalignant strictures, achalasia and other esophageal motility disorders, esophagitis, and esophageal webs and rings. (See
         <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">
          "Approach to the evaluation of dysphagia in adults", section on 'Symptom-based differential diagnosis'
         </a>
         .)
        </p>
        <p>
         The differential diagnosis of an esophageal mass includes lesions that typically arise beneath an intact mucosa, including gastrointestinal stromal tumors, leiomyomas and leiomyosarcomas, as well as high-grade neuroendocrine neoplasms (extrapulmonary small cell cancers); all of these are rare. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Location'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Esophagus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">
          "High-grade gastroenteropancreatic neuroendocrine neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3358072905">
         <span class="h3">
          Other symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regurgitation of saliva or food uncontaminated by gastric secretions may also occur. Aspiration pneumonia is infrequent. Hoarseness and/or cough may occur if the recurrent laryngeal nerve is invaded by either the primary tumor or associated nodal metastases.
        </p>
        <p>
         Chronic gastrointestinal blood loss from esophageal and EGJ cancer is common and may result in iron deficiency anemia [
         <a href="#rid8">
          8
         </a>
         ]. However, patients seldom notice melena, hematemesis, or blood in regurgitated food. Acute upper gastrointestinal bleeding as a result of tumor erosion into the aorta or pulmonary or bronchial arteries is rare.
        </p>
        <p>
         Tracheobronchial fistulas are a late complication. They are caused by direct invasion of tumor through the esophageal wall and into the mainstem bronchus. Such patients often present with intractable coughing or recurrent pneumonias. Stent placement is the treatment of choice. (See
         <a class="medical medical_review" href="/z/d/html/115157.html" rel="external">
          "Tracheo- and broncho-esophageal fistulas in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2273.html" rel="external">
          "Endoscopic palliation of esophageal cancer"
         </a>
         .)
        </p>
        <p>
         Signs or symptoms referable to distant metastatic disease often occur. The most common sites of distant metastases are the liver, lungs, bones, and adrenal glands [
         <a href="#rid9">
          9
         </a>
         ]. Adenocarcinomas most frequently metastasize to intraabdominal sites (liver, peritoneum), while metastases from SCCs are usually intrathoracic. However, many other sites are described, including cutaneous, muscle, and brain metastases [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1262037624">
         <span class="h2">
          Cervical esophageal tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Between 5 and 6 percent of esophageal cancers arise in the cervical portion of the esophagus, which is 6 to 8 cm long and extends from the hypopharynx (upper esophageal sphincter) to the sternal notch  (
         <a class="graphic graphic_table graphicRef111351" href="/z/d/graphic/111351.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef111260" href="/z/d/graphic/111260.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ]. Most patients have locally advanced disease at the time of diagnosis, sometimes with extension to the hypopharynx. In retrospective series, the most common complaints are weight loss and dysphagia, and 11 to 24 percent have hoarseness as a presenting symptom [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of esophageal cancer requires a histologic examination of tumor tissue. A diagnostic biopsy may be obtained by upper endoscopy or, if metastases are present, by image-guided biopsy of a metastatic site.
        </p>
        <p class="headingAnchor" id="H750159883">
         <span class="h2">
          Endoscopic biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early esophageal cancers appear endoscopically as superficial plaques, nodules, or ulcerations  (
         <a class="graphic graphic_picture graphicRef55091" href="/z/d/graphic/55091.html" rel="external">
          picture 1
         </a>
         ). Advanced lesions appear as strictures  (
         <a class="graphic graphic_picture graphicRef55542" href="/z/d/graphic/55542.html" rel="external">
          picture 2
         </a>
         ), ulcerated masses  (
         <a class="graphic graphic_picture graphicRef78958" href="/z/d/graphic/78958.html" rel="external">
          picture 3
         </a>
         ), circumferential masses  (
         <a class="graphic graphic_picture graphicRef67522" href="/z/d/graphic/67522.html" rel="external">
          picture 4
         </a>
         ), or large ulcerations. (See
         <a class="medical medical_review" href="/z/d/html/13928.html" rel="external">
          "Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)"
         </a>
         .)
        </p>
        <p>
         While endoscopic visualization of a large mucosal mass is nearly pathognomonic of esophageal cancer, biopsy must be performed to confirm the diagnosis.
        </p>
        <p>
         The greater the number of biopsies (up to seven), the higher the diagnostic accuracy. As an example, in a series of 202 consecutive patients, 47 of whom had gastric or esophageal carcinoma, the percentages of correct diagnoses of esophageal carcinoma were as follows [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First biopsy – 93 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Four biopsies – 95 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seven biopsies – 98 percent
        </p>
        <p>
        </p>
        <p>
         For small lesions, endoscopic resection of the entire lesion may be feasible. Following histologic analysis, endoscopic resection alone may represent suitable therapy if the tumor is small and superficial (see
         <a class="medical medical_review" href="/z/d/html/2673.html" rel="external">
          "Overview of endoscopic resection of gastrointestinal tumors", section on 'Esophageal cancer'
         </a>
         ).
        </p>
        <p>
         Assessment and endoscopic management of superficial esophageal cancer are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2673.html" rel="external">
          "Overview of endoscopic resection of gastrointestinal tumors", section on 'Esophageal cancer'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2494.html" rel="external">
          "Management of superficial esophageal cancer", section on 'Initial assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PRETREATMENT STAGING EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of esophageal cancer is strongly associated with disease stage. Accurate clinical staging of both local tumor extent and the presence or absence of distant metastases is critical for estimating prognosis and selecting the appropriate treatment strategy.
        </p>
        <p class="headingAnchor" id="H982579162">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the diagnosis of esophageal cancer is established, pretreatment staging includes an evaluation for both locoregional disease and distant metastases:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endoscopic ultrasound (EUS) is the preferred method for locoregional staging. For patients with a thoracic esophageal tumor at or above the carina, bronchoscopy is also indicated. For cervical squamous cell carcinomas (SCCs), flexible laryngoscopy to assess local disease spread and exclude a synchronous malignancy of the head and neck is generally recommended. (See
         <a class="local">
          'Locoregional staging'
         </a>
         below and
         <a class="local">
          'Bronchoscopy and laryngoscopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The evaluation for distant metastases includes tomographic testing, including contrast-enhanced computed tomography (CT) of the neck, chest, and abdomen; whole-body integrated fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT; EUS; and sometimes diagnostic laparoscopy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Integrated FDG-PET/CT scans are more sensitive than contrast-enhanced CT for detecting metastatic disease and are now indicated for the detection of occult metastases; if they are not detected on the initial staging CT. Use of preoperative PET/CT in the pretreatment staging evaluation results in a change in management (usually upstaging and thus avoidance of unnecessary surgery) in up to 20 percent of patients. At some institutions, PET with a diagnostic, contrast-enhanced CT is carried out with intravenous (IV) contrast, which replaces the need for a separate contrast-enhanced CT, but this practice is not widespread. (See
         <a class="local">
          'CT, PET, and integrated PET/CT'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         EUS can visualize liver metastases &lt;1 cm in the left lobe of the liver and malignant ascites; EUS-guided fine-needle aspiration (FNA) or fine needle biopsy (FNB) can get tissue from either of these sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Invasive staging (laparoscopy, thoracoscopy) may be used to enhance or replace EUS or imaging; however, no study has compared these approaches with EUS plus PET/CT, which are superior to conventional imaging for detecting distant metastases. Some clinicians advocate diagnostic laparoscopy for patients with potentially resectable clinical T3/T4 adenocarcinomas arising at the EGJ or cardia or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. We do not utilize thoracoscopy for patients who have access to integrated PET/CT. (See
         <a class="local">
          'Laparoscopy and thoracoscopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Routine brain imaging is not a cost-effective or necessary evaluation unless symptoms or signs raise suspicion for brain metastases. (See
         <a class="local">
          'Other tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          TNM staging criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tumor, node, metastasis (TNM) staging system of the combined American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) for esophageal cancer is used universally. In the most recent (2017, eighth edition) revision [
         <a href="#rid11">
          11,16
         </a>
         ], tumors involving the EGJ with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal cancer. In contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers, as are all cardia cancers not involving the EGJ, even if they are within 2 cm of the EGJ. Thus, regardless of histology, all esophageal tumors arising in the cervical, thoracic, or abdominal esophagus and those involving the EGJ that have an epicenter within 2 cm of the EGJ  (
         <a class="graphic graphic_table graphicRef111351" href="/z/d/graphic/111351.html" rel="external">
          table 3
         </a>
         ) share the same criteria for T, N, and M stage designation  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ). However, there are separate stage groupings for SCC and adenocarcinoma regardless of site. Pathologic staging is indicated by a p designation, and pathologic staging after preoperative therapy is indicated by a yp prefix.
        </p>
        <p>
         Histology-specific stage groupings, initially introduced in 2010, were based on an analysis of worldwide data from 4627 patients with cancer of the esophagus or EGJ who underwent surgery alone. Among patients with node-negative tumors, prognosis was dependent on not only T stage but also on histology and grade of differentiation, and for SCCs, tumor location [
         <a href="#rid17">
          17
         </a>
         ]. Subsequently, investigators used updated data from the Worldwide Esophageal Cancer Collaboration to develop the following figures to illustrate risk-adjusted survival according to clinical, pathologic, and posttreatment pathologic stage for adenocarcinomas  (
         <a class="graphic graphic_figure graphicRef111241" href="/z/d/graphic/111241.html" rel="external">
          figure 2
         </a>
         ) and SCCs  (
         <a class="graphic graphic_figure graphicRef111244" href="/z/d/graphic/111244.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid18">
          18-23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Regional lymph nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to 2010, the specific lymph node groups that were considered regional for esophageal cancer varied according to the anatomic compartment and location within the esophagus. Data suggesting the prognostic importance of the number of involved lymph nodes rather than the location (particularly in the surgical specimen after chemoradiotherapy [
         <a href="#rid24">
          24-32
         </a>
         ]) led to a change in the N stage classification in the 2010 (and subsequent 2017) revision of the AJCC/UICC staging system, with an emphasis on the number of involved nodes rather than location. Regional lymph nodes for all locations in the esophagus extend from periesophageal lymph nodes to celiac nodes and are illustrated in the figure  (
         <a class="graphic graphic_figure graphicRef111319" href="/z/d/graphic/111319.html" rel="external">
          figure 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Locoregional staging
         </span>
        </p>
        <p class="headingAnchor" id="H456002256">
         <span class="h3">
          EUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS uses a high-frequency ultrasound transducer to provide detailed images of esophageal masses and their relationship with the five-layered structure of the esophageal wall. (See
         <a class="medical medical_review" href="/z/d/html/2657.html" rel="external">
          "Endoscopic ultrasound: Examination of the upper gastrointestinal tract"
         </a>
         .)
        </p>
        <p>
         EUS is the most accurate technique for locoregional staging of invasive esophageal cancer.
        </p>
        <p class="headingAnchor" id="H2095283833">
         <span class="h4">
          T stage
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sensitivity and specificity rates of EUS for the correct evaluation of T stage are 81 to 92, and 94 to 97 percent, respectively; in general, EUS performs better with advanced (eg, T4) than with early (ie, T1) disease [
         <a href="#rid33">
          33
         </a>
         ]. Briefly:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the EUS identifies only mucosal (T1a) disease, endoscopic mucosal resection (EMR) is usually the next step to endoscopic resection of the tumor and precisely define the depth of invasion. The pathology result from the EMR or endoscopic submucosal dissection (particularly the presence or absence of lymphovascular invasion) is used to guide therapeutic decisions. (See
         <a class="medical medical_review" href="/z/d/html/2494.html" rel="external">
          "Management of superficial esophageal cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer", section on 'EUS for T staging of superficial tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By EUS, T2, T3, and T4 tumors appear as strictures, ulcerations, or exophytic masses  (
         <a class="graphic graphic_picture graphicRef55542" href="/z/d/graphic/55542.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef78958" href="/z/d/graphic/78958.html" rel="external">
          picture 3
         </a>
         ). T2 tumors involve the muscularis propria but do not have transmural invasion through the esophageal wall. By EUS, they appear as irregular hypoechoic masses involving the esophageal wall, leaving the muscularis intact, as evidenced by a smooth contour of the mass and muscularis propria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         T3 and T4 tumors are both intra- and extraesophageal. Masses that extend into the adventitia are stage T3. T4 masses have invaded through the muscularis propria and adventitia to involve locoregional structures such as pericardium, atrium aorta, vena cava, bronchus, diaphragm, peritoneum, or pleura.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The finding of an irregular outer border with invasion through the wall of the esophagus may or may not indicate local unresectability. In the eighth edition TNM classification  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ), tumors classified as T4 are divided into those that are potentially resectable (T4a: tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum) and those that are categorically unresectable (T4b: invasion of other adjacent structures, such as the aorta, vertebral body, or airway). (See
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer", section on 'EUS for staging locally advanced tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer", section on 'Accuracy of EUS for determining unresectability'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A caveat for EUS staging of esophageal wall penetration (T staging) is that the instrument cannot traverse a tumor-induced stenosis (which occurs in approximately 30 percent of cases). In these settings, EUS may under-stage the tumor because the entire lesion and the celiac axis as well as liver are not seen. It is controversial as to whether to dilate the esophagus for the purpose of a staging examination, since perforations may occur. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer", section on 'EUS for staging locally advanced tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3351662220">
         <span class="h4">
          Regional nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS achieves nodal staging of esophageal cancer by ultrasound image characteristics and FNA or FNB tissue acquisition:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endosonographic criteria that are suggestive of malignant involvement of the visible lymph nodes include width &gt;10 mm, round shape, smooth border, and echo-poor pattern  (
         <a class="graphic graphic_table graphicRef66591" href="/z/d/graphic/66591.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef57813" href="/z/d/graphic/57813.html" rel="external">
          image 1
         </a>
         ). Of these, echo-poor pattern and width &gt;10 mm are the most specific for malignancy. When all four features are present, there is an 80 to 100 percent chance of metastatic involvement. However, only 25 percent of malignant nodes will have all of these features. These results demonstrate the limitations of EUS criteria for use in preoperative lymph node staging. (See
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer", section on 'EUS for preoperative lymph node staging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EUS-guided FNA or FNB may improve the accuracy of N staging by providing cytologic confirmation of metastatic disease from accessible nodes, as long as the primary tumor is not in the pathway of the needle. Sensitivity, specificity, and accuracy of EUS-guided FNA for locoregional lymph nodes are all over 85 percent when surgical resection specimen or cytology results are considered the gold standard. (See
         <a class="medical medical_review" href="/z/d/html/2663.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with esophageal cancer", section on 'Endoscopic ultrasound-guided fine-needle aspiration biopsy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The endoscopic finding of a malignant node in the celiac area remote from the primary tumor (ie, for SCCs or for lesions in the upper or middle thoracic esophagus  (
         <a class="graphic graphic_figure graphicRef111260" href="/z/d/graphic/111260.html" rel="external">
          figure 1
         </a>
         )) was previously an indicator of unresectability and was staged as M1a metastatic disease. However, celiac nodal metastases are scored as regional nodal disease in the newest 2017 TNM revision  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ) regardless of the primary tumor location or histology [
         <a href="#rid11">
          11,34
         </a>
         ]. Nevertheless, prognosis is poor in such cases, even if the primary tumor is located in the distal esophagus or EGJ [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Regional lymph nodes'
         </a>
         above and
         <a class="local">
          'TNM staging criteria'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H258337850">
         <span class="h3">
          Bronchoscopy and laryngoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative bronchoscopy with biopsy and brush cytology is advocated by some (including the National Cooperative Cancer Network [NCCN]) as the last investigation in the staging workup for patients with locally advanced, nonmetastatic tumors located at or above the carina (ie, upper esophageal and cervical SCCs) [
         <a href="#rid5">
          5
         </a>
         ]. In a study of 116 consecutive patients with potentially operable upper or cervical esophageal carcinoma, bronchoscopy was superior to CT and excluded 10 percent of patients from surgery because of airway invasion [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         For cervical SCCs, which are often diagnosed by ear, nose and throat (ENT) clinicians, flexible laryngoscopy is used to assess local disease extent and to detect a synchronous malignancy of the head and neck. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Incidence of second and multiple primaries'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">
          "Management of locally advanced, unresectable and inoperable esophageal cancer", section on 'Cervical esophageal tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3446715773">
         <span class="h2">
          Evaluation for distant metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common sites of distant metastases in patients with esophageal cancer are the liver, lungs, bones, and adrenal glands [
         <a href="#rid9">
          9
         </a>
         ]. Adenocarcinomas most frequently metastasize to intraabdominal sites (liver, peritoneum), while metastases from SCCs are typically intrathoracic. (See
         <a class="local">
          'Regional lymph nodes'
         </a>
         above.)
        </p>
        <p>
         M staging is carried out with cross-sectional imaging (contrast-enhanced CT, PET/CT scanning), EUS, and for selected patients, diagnostic laparoscopy.
        </p>
        <p class="headingAnchor" id="H1231123333">
         <span class="h3">
          EUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS can visualize liver metastases of &lt;1 cm and malignant ascites. EUS-guided FNA or FNB can provide a tissue diagnosis for liver metastases and FNA may be performed to sample malignant ascites. (See
         <a class="medical medical_review" href="/z/d/html/2656.html" rel="external">
          "Endoscopic ultrasound-guided fine needle aspiration in the gastrointestinal tract", section on 'Other lesions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3265018875">
         <span class="h3">
          CT, PET, and integrated PET/CT
         </span>
         <span class="headingEndMark">
          —
         </span>
         FDG-PET and integrated PET/CT scans are useful to detect occult metastatic disease in patients who are otherwise believed to be surgical candidates after routine staging with conventional contrast-enhanced helical CT. Integrated PET/CT imaging is increasingly favored over PET alone due to better spatial resolution. It involves performance of both PET and CT sequentially during a single visit on a hybrid PET/CT scanner. However, the CT component of integrated PET/CT imaging is performed in most institutions without the use of IV contrast, which compromises the detection of small metastases both within and outside the liver. In the absence of IV contrast, an integrated PET/CT cannot substitute for a dedicated IV-contrast-enhanced CT. At some institutions, PET/CT is carried out with IV contrast. This may replace the need for a separate contrast-enhanced CT, but this practice is not widespread.
        </p>
        <p>
         While relatively inexpensive, contrast-enhanced (oral plus IV) helical CT has a limited ability to identify locally advanced (T4  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         )) disease and subclinical distant metastatic disease, particularly in the peritoneal cavity [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         FDG-PET is more sensitive than contrast-enhanced CT or EUS for the detection of distant metastases [
         <a href="#rid37">
          37,39-44
         </a>
         ]. The addition of PET to the preoperative assessment alters management in 5 to 20 percent of cases, mainly by detecting occult metastases (ie, upstaging) that reduces the number of patients who undergo needless surgery [
         <a href="#rid9">
          9,39-42,45,46
         </a>
         ]. The improved sensitivity of PET for the detection of metastatic disease makes it
         <strong>
          potentially
         </strong>
         the most cost-effective method of identifying patients with occult metastases for whom curative therapy should not be pursued [
         <a href="#rid38">
          38,45,47,48
         </a>
         ].
        </p>
        <p>
         A major drawback of PET for the evaluation of the primary site and nodal metastases is its poor spatial resolution that makes it difficult to localize the anatomic location of the FDG uptake. This limitation is significantly reduced by the use of integrated PET/CT imaging, a technique in which both PET and CT are performed sequentially during a single visit on a hybrid PET/CT scanner. The PET and CT images are then co-registered using fusion software, enabling the physiologic data obtained on PET to be localized according to the anatomic CT images  (
         <a class="graphic graphic_diagnosticimage graphicRef97798" href="/z/d/graphic/97798.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
         Limited data suggest a greater accuracy of integrated PET/CT over PET alone in patients with cancer, including esophageal cancer [
         <a href="#rid49">
          49,50
         </a>
         ], and most institutions are now performing integrated PET/CT rather than PET alone because of the better spatial resolution. At most institutions, the CT component of integrated PET/CT imaging is performed without the use of IV contrast material or in partial/complete expiration, precluding the optimal detection of small lung and liver metastases. Increasingly, PET/CT is carried out with IV contrast, but this practice is not widespread [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Measurement of the standardized uptake value (SUV), which reflects the metabolic activity of the tumor, may also be a prognostic factor. In a meta-analysis of seven studies that evaluated the impact of the SUV on overall survival, high SUV predicted worse survival [
         <a href="#rid52">
          52
         </a>
         ]. However, in a large retrospective series that was not included in the meta-analysis, an initially high SUV did not correlate with worse survival [
         <a href="#rid53">
          53
         </a>
         ]. In fact, the results suggested a better response to preoperative chemoradiotherapy in the high SUV group. The value of FDG-PET as a predictive marker of response to neoadjuvant therapy remains uncertain, however [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Suspicious PET findings should be confirmed with biopsy before excluding a patient from surgical consideration, given the high rate of false-positive findings [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         As with contrast-enhanced CT scanning alone, PET/CT is of limited value for staging the extent of locoregional tumor, particularly nodal status [
         <a href="#rid37">
          37
         </a>
         ]. This may be due, at least in part, to high FDG uptake in the primary esophageal malignancy, which obscures increased FDG uptake in the regional nodes, and/or low sensitivity for small involved lymph nodes. Furthermore, PET/CT is not consistently able to differentiate the depth of primary tumor invasion. EUS is more accurate than either PET/CT or contrast-enhanced CT alone [
         <a href="#rid56">
          56
         </a>
         ], and it is the locoregional tumor staging modality of choice. (See
         <a class="local">
          'EUS'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h4">
          PET restaging after induction therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Integrated PET/CT may be also be useful for restaging after preoperative therapy.
        </p>
        <p>
         Limited experience suggests that whole-body PET/CT imaging detects distant metastases in approximately 8 percent of patients following induction chemoradiotherapy with or without induction chemotherapy [
         <a href="#rid57">
          57
         </a>
         ]. In many of these cases, the metastases were located in sites (eg, skeletal muscle, subcutaneous soft tissue, brain, thyroid) that are not imaged well by conventional radiographic staging techniques. Some clinicians order a post-induction-therapy PET/CT approximately four weeks after the completion of induction therapy. This is a method to assess for distant metastatic disease and potentially prevent unneeded surgery, an approach that is endorsed in the consensus-based NCCN guidelines [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'PET-directed therapy'
         </a>
         .)
        </p>
        <p>
         In addition to detecting otherwise occult metastatic disease, post-induction-therapy FDG-PET provides information on metabolic response in the primary tumor that may be clinically useful in the selection of subsequent therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early data from retrospective series suggest that post-chemoradiotherapy FDG-PET scanning may serve to identify those patients for whom surgery might be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other data suggest that responses observed on PET scans during induction chemotherapy have significant predictive and prognostic benefit [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These data are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus", section on 'Utility of postinduction therapy PET scans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'PET-directed therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Laparoscopy and thoracoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for diagnostic laparoscopy for patients who appear to have potentially resectable esophageal or EGJ carcinomas is controversial, and there is no consensus on this issue from expert groups. We reserve diagnostic laparoscopy for patients who, after conventional pretreatment staging studies, appear to have potentially resectable, clinical T3 or T4  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ), Siewert II to III (ie, located between 1 cm proximal and 5 cm distal to the anatomical squamocolumnar junction or Z-line  (
         <a class="graphic graphic_figure graphicRef76055" href="/z/d/graphic/76055.html" rel="external">
          figure 5
         </a>
         )) adenocarcinomas of the EGJ, or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. We do not perform thoracoscopic staging in patients who have access to PET/CT.
        </p>
        <p>
         In order to limit aggressive treatment to patients with locally advanced disease, diagnostic laparoscopy is sometimes performed to detect occult intraperitoneal metastases in patients with distal esophageal and EGJ adenocarcinomas [
         <a href="#rid59">
          59-61
         </a>
         ]. Intraperitoneal metastases are notoriously difficult to diagnose noninvasively by either CT or PET.
        </p>
        <p>
         Laparoscopic (and thoracoscopic) staging procedures have also been examined for their potential to more accurately stage regional lymph nodes (particularly celiac and intrathoracic) as compared with EUS [
         <a href="#rid62">
          62-64
         </a>
         ]. As an example, in a multi-institutional study conducted by the Cancer and Leukemia Group B (CALGB), noninvasive imaging (CT, magnetic resonance imaging [MRI], and EUS) incorrectly staged (either false-negative lymph nodes or false-positive metastatic disease) 50, 40, and 30 percent of patients, respectively, as assessed by thoracoscopic or laparoscopic staging [
         <a href="#rid62">
          62
         </a>
         ]. An important limitation of this study was that EUS was performed without FNA, thus limiting the accuracy of noninvasive imaging.
        </p>
        <p>
         Although the available data support the view that invasive staging is more accurate than EUS or CT alone; however, no study has compared this approach with EUS plus integrated PET/CT scanning, which is superior to conventional imaging modalities for detecting distant metastases.
        </p>
        <p>
         The need for diagnostic laparoscopy for patients who appear to have potentially resectable distal esophageal and EGJ adenocarcinomas is controversial, and there is no consensus on this issue from expert groups; none of these groups provides guidelines for the use of diagnostic thoracoscopy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consensus-based guidelines from the NCCN consider diagnostic laparoscopy to be "optional" for patients with EGJ tumors and no evidence of metastatic disease [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidelines from the European Society for Medical Oncology (ESMO) advocate diagnostic laparoscopy for all patients with locally advanced (T3/T4) adenocarcinomas of the EGJ infiltrating the gastric cardia [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sages.org%2Fpublications%2Fguidelines%2Fguidelines-for-diagnostic-laparoscopy%2F&amp;token=O3fJBIeOdk%2FWVKUN1AlzeUYy9H%2FBXKf49bxbifIPbwKAz5eKqcxgI%2BKrUYgGjOxbPFGVb1U8zr%2BCoN3%2FPu9DFjwPtG1pZvobZd4NC%2F5dcTU%3D&amp;TOPIC_ID=2502" target="_blank">
          Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
         </a>
         states that patients who are considered to be candidates for curative resection (early stage esophageal cancer with no evidence of distant or lymph node metastases on high-quality preoperative imaging) may benefit from staging laparoscopy (grade B).
        </p>
        <p>
        </p>
        <p>
         We reserve diagnostic laparoscopy for patients who, after conventional pretreatment staging studies, appear to have potentially resectable, clinical T3 or T4  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ), Siewert II to III (ie, located between 1 cm proximal and 5 cm distal to the anatomical squamocolumnar junction or Z-line  (
         <a class="graphic graphic_figure graphicRef76055" href="/z/d/graphic/76055.html" rel="external">
          figure 5
         </a>
         )) adenocarcinomas of the EGJ, or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. The surgical approach, diagnostic accuracy, and yield of diagnostic laparoscopy for esophageal cancer are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15106.html" rel="external">
          "Diagnostic staging laparoscopy for digestive system cancers", section on 'Esophagogastric junction and gastric cancer'
         </a>
         .)
        </p>
        <p>
         Another approach, laparoscopic ultrasound, may provide the benefits of both locoregional and intraperitoneal staging [
         <a href="#rid65">
          65-67
         </a>
         ]. In a study of 26 patients with gastric or esophageal cancers, T and N staging with laparoscopic ultrasound were comparable with results from EUS [
         <a href="#rid65">
          65
         </a>
         ]. The accuracy of M staging with laparoscopic ultrasound was better than with laparoscopy alone or CT (89 versus 44 and 64 percent, respectively). No randomized trials or large reviews have been performed to determine if laparoscopic ultrasound offers a significant advantage over laparoscopy alone for detecting unresectable disease in esophageal cancer. (See
         <a class="medical medical_review" href="/z/d/html/15106.html" rel="external">
          "Diagnostic staging laparoscopy for digestive system cancers", section on 'Laparoscopic ultrasound'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3262939498">
         <span class="h3">
          Other tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consensus-based guidelines for staging, such as those published by the NCCN [
         <a href="#rid5">
          5
         </a>
         ] and ESMO [
         <a href="#rid4">
          4
         </a>
         ], do not recommend routine pretreatment brain imaging for patients with esophageal or EGJ cancers. Brain metastases have been considered uncommon in patients with esophageal cancer (published incidence &lt;5 percent [
         <a href="#rid68">
          68,69
         </a>
         ]). However, in more contemporary esophageal cancer cohorts with higher percentages of adenocarcinoma, the incidence of brain metastases may be higher (13 percent in one series [
         <a href="#rid70">
          70
         </a>
         ]). Despite these data, however, routine brain imaging is not considered cost effective or necessary as part of the routine staging evaluation unless symptoms or signs raise suspicion for brain metastases.
        </p>
        <p class="headingAnchor" id="H3217766884">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120117.html" rel="external">
          "Society guideline links: Esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86360486">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15732.html" rel="external">
          "Patient education: Upper endoscopy (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16832.html" rel="external">
          "Patient education: Esophageal cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1992.html" rel="external">
          "Patient education: Upper endoscopy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Patients with advanced thoracic or cervical esophageal carcinoma usually present with progressive dysphagia and weight loss. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishing the diagnosis
         </strong>
         – The diagnosis of esophageal or esophagogastric junction (EGJ) cancer is usually established by endoscopic biopsy. Early cancers may appear as superficial plaques, nodules, or ulcerations  (
         <a class="graphic graphic_picture graphicRef55091" href="/z/d/graphic/55091.html" rel="external">
          picture 1
         </a>
         ). Advanced lesions may appear as strictures  (
         <a class="graphic graphic_picture graphicRef55542" href="/z/d/graphic/55542.html" rel="external">
          picture 2
         </a>
         ), ulcerated masses  (
         <a class="graphic graphic_picture graphicRef78958" href="/z/d/graphic/78958.html" rel="external">
          picture 3
         </a>
         ), circumferential masses  (
         <a class="graphic graphic_picture graphicRef67522" href="/z/d/graphic/67522.html" rel="external">
          picture 4
         </a>
         ), or large ulcerations. The endoscopic appearance of a large mucosal mass is frequently diagnostic of esophageal cancer. Biopsies confirm the diagnosis in more than 90 percent of cases. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Staging and pretreatment assessment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) for esophageal cancer is used universally  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the most recent (eighth edition, 2017) version, tumors involving the EGJ with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal cancers. In contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers, as are all cardia cancers not involving the EGJ, even if they are within 2 cm of the EGJ  (
         <a class="graphic graphic_table graphicRef111351" href="/z/d/graphic/111351.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'TNM staging criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Once the diagnosis of esophageal cancer is established, selection of the appropriate therapeutic approach for an esophageal cancer is highly dependent on the accuracy of pretreatment assessment. The pretreatment staging assessment includes an evaluation for both locoregional disease extent and distant metastases:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Endoscopic ultrasound (EUS) is the preferred method for locoregional staging. Preoperative bronchoscopy with biopsy and brush cytology is indicated for patients with locally advanced, nonmetastatic tumors that are located at or above the level of the carina, and flexible laryngoscopy is generally recommended for cervical squamous cell carcinomas (SCCs). (See
         <a class="local">
          'Locoregional staging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         All patients should undergo contrast-enhanced CT of the neck, chest, and abdomen to evaluate for distant metastases. For selected patients, whole-body integrated fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT, EUS, and/or diagnostic laparoscopy may be indicated:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         FDG-PET/CT is more sensitive than contrast-enhanced CT for detecting metastases and are now widely used to detect occult metastases if metastases are not seen on the initial staging CT scans. At some institutions, PET/CT is carried out with intravenous contrast, and this might effectively replace the need for a separate contrast-enhanced CT, but this practice is not widespread. Suspicious PET/CT findings should be histologically confirmed before excluding a patient from surgical consideration. (See
         <a class="local">
          'CT, PET, and integrated PET/CT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         EUS-guided fine-needle aspiration (FNA) or fine needle biopsy can provide a tissue diagnosis for suspected liver metastases and FNA may be done to diagnose malignant ascites.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The role of staging laparoscopy is controversial. We reserve diagnostic laparoscopy for patients with potentially resectable clinical T3/T4  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 2
         </a>
         ) adenocarcinomas arising within the abdominal portion of the esophagus  (
         <a class="graphic graphic_table graphicRef111351" href="/z/d/graphic/111351.html" rel="external">
          table 3
         </a>
         ) or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. We do not utilize thoracoscopy for patients who have access to EUS and integrated PET/CT. (See
         <a class="local">
          'Laparoscopy and thoracoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Routine brain imaging is not indicated unless symptoms or signs raise suspicion for brain metastases. (See
         <a class="local">
          'Other tests'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol 2016; 41:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baquet CR, Commiskey P, Mack K, et al. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005; 97:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:992.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dandara C, Robertson B, Dzobo K, et al. Patient and tumour characteristics as prognostic markers for oesophageal cancer: a retrospective analysis of a cohort of patients at Groote Schuur Hospital. Eur J Cardiothorac Surg 2016; 49:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavallin F, Scarpa M, Cagol M, et al. Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series. Ann Surg 2018; 267:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schatz RA, Rockey DC. Gastrointestinal Bleeding Due to Gastrointestinal Tract Malignancy: Natural History, Management, and Outcomes. Dig Dis Sci 2017; 62:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000; 25:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaheen O, Ghibour A, Alsaid B. Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review. Gastroenterol Res Pract 2017; 2017:1657310.
          </a>
         </li>
         <li class="breakAll">
          Rice TW, Kelsen D, Blackstone EH, et al. Esophagus and esophagogastric junction. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.185. Corrected at 4th printing, 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao CN, Luo JW, Gao L, et al. Primary radiotherapy compared with primary surgery in cervical esophageal cancer. JAMA Otolaryngol Head Neck Surg 2014; 140:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2015; 116:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triboulet JP, Mariette C, Chevalier D, Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 2001; 136:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82:228.
          </a>
         </li>
         <li class="breakAll">
          Ajani JA, In H, Sano T, et al. Stomach. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.203.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010; 116:3763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Apperson-Hansen C, DiPaola LM, et al. Worldwide Esophageal Cancer Collaboration: clinical staging data. Dis Esophagus 2016; 29:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Lerut TE, Orringer MB, et al. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Dis Esophagus 2016; 29:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Chen LQ, Hofstetter WL, et al. Worldwide Esophageal Cancer Collaboration: pathologic staging data. Dis Esophagus 2016; 29:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Ishwaran H, Kelsen DP, et al. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus 2016; 29:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus 2016; 29:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus 2016; 29:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005; 104:2365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CS, Chang SC, Wei YH, et al. Prognostic variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2009; 87:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang HL, Chen LQ, Liu RL, et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus 2010; 23:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006; 132:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogoevski D, Onken F, Koenig A, et al. Is it time for a new TNM classification in esophageal carcinoma? Ann Surg 2008; 247:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008; 14:1479.
          </a>
         </li>
         <li class="breakAll">
          American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boonstra JJ, Koppert LB, Wijnhoven BP, et al. Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement. J Surg Oncol 2009; 100:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riedel M, Hauck RW, Stein HJ, et al. Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study. Chest 1998; 113:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008; 98:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romagnuolo J, Scott J, Hawes RH, et al. Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. Gastrointest Endosc 2002; 55:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18:3202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007; 133:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Räsänen JV, Sihvo EI, Knuuti MJ, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Westreenen HL, Heeren PA, van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002; 137:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am 2000; 10:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace MB, Nietert PJ, Earle C, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002; 74:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22:4357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bar-Shalom R, Guralnik L, Tsalic M, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2005; 32:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mawlawi O, Erasmus JJ, Munden RF, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 2006; 186:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan L, Gu P, Huang G, et al. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009; 21:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009; 4:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010; 254:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erhunmwunsee L, Englum BR, Onaitis MW, et al. Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions. Ann Surg Oncol 2015; 22:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giganti F, Ambrosi A, Petrone MC, et al. Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study. Br J Radiol 2016; 89:20160087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007; 109:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman KA, Hall N, Bekaii-Saab TS, et al. Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. J Clin Oncol 2018; 36S:ASCO #4012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushik N, Khalid A, Brody D, et al. Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer. Ann Thorac Surg 2007; 83:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yau KK, Siu WT, Cheung HY, et al. Immediate preoperative laparoscopic staging for squamous cell carcinoma of the esophagus. Surg Endosc 2006; 20:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryan RT, Cruickshank NR, Needham SJ, et al. Laparoscopic peritoneal lavage in staging gastric and oesophageal cancer. Eur J Surg Oncol 2001; 27:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasna MJ, Reed CE, Nedzwiecki D, et al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg 2001; 71:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasna MJ, Jiao X, Mao YS, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. Surg Laparosc Endosc Percutan Tech 2002; 12:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luketich JD, Schauer P, Landreneau R, et al. Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. J Thorac Cardiovasc Surg 1997; 114:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finch MD, John TG, Garden OJ, et al. Laparoscopic ultrasonography for staging gastroesophageal cancer. Surgery 1997; 121:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakelin SJ, Deans C, Crofts TJ, et al. A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma. Eur J Radiol 2002; 41:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samee A, Moorthy K, Jaipersad T, et al. Evaluation of the role of laparoscopic ultrasonography in the staging of oesophagogastric cancers. Surg Endosc 2009; 23:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg JS, Suki D, Hanbali F, et al. Metastasis of esophageal carcinoma to the brain. Cancer 2003; 98:1925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabrielsen TO, Eldevik OP, Orringer MB, Marshall BL. Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. AJNR Am J Neuroradiol 1995; 16:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RS, Miller RC. Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol 2011; 17:2407.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2502 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26851752" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The epidemic of oesophageal carcinoma: Where are we now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16334494" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13130116" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Population attributable risks of esophageal and gastric cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35914638" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35914638" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25870217" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Patient and tumour characteristics as prognostic markers for oesophageal cancer: a retrospective analysis of a cohort of patients at Groote Schuur Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27759616" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28032204" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Gastrointestinal Bleeding Due to Gastrointestinal Tract Malignancy: Natural History, Management, and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11079584" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28659974" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28659974" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25233363" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Primary radiotherapy compared with primary surgery in cervical esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26233590" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585510" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7054024" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7054024" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20564099" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27731549" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Worldwide Esophageal Cancer Collaboration: clinical staging data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27731548" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27731547" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Worldwide Esophageal Cancer Collaboration: pathologic staging data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27905170" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27905171" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27905172" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290058" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15719440" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16245310" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19324127" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prognostic variables in thoracic esophageal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092342" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19392846" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17140960" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18216546" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18362626" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Is it time for a new TNM classification in esophageal carcinoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18330935" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18330935" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19653239" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9515844" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212745" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Staging investigations for oesophageal cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11979245" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10986052" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9016218" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9307472" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Improvement in staging of esophageal cancer with the addition of positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543468" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17320575" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14527917" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15623445" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12215149" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Positron emission tomography in the initial staging of esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10967751" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical staging of esophageal carcinoma. CT, EUS, and PET.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12400740" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15514377" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15838691" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The additional value of PET/CT over PET in FDG imaging of oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16423932" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19352191" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487968" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20177086" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25234017" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27767330" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17146785" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17532386" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Endoscopic ultrasound compared with laparoscopy for staging esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16362473" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Immediate preoperative laparoscopic staging for squamous cell carcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11373108" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Laparoscopic peritoneal lavage in staging gastric and oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11308139" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12193812" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9375612" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9001545" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Laparoscopic ultrasonography for staging gastroesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11809546" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18548310" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Evaluation of the role of laparoscopic ultrasonography in the staging of oesophagogastric cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14584076" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Metastasis of esophageal carcinoma to the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8693995" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21633640" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Incidence of brain metastasis in patients with esophageal carcinoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
